Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.97 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | FABP7 | O15540 | 1/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29482640 | 1.00 | KMT2A (0.97) | KMT2AHTTEPHX2CASP3FABP7 | |
| SCHEMBL178760 | 0.99 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3FABP7 | |
| SCHEMBL178762 | 0.99 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3FABP7 | |
| SCHEMBL25143 | 0.99 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3FABP7 | |
| SCHEMBL2182769 | 0.99 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3FABP7 | |
| SCHEMBL178758 | 0.99 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3FABP7 | |
| SCHEMBL178759 | 0.99 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3FABP7 | |
| SCHEMBL178761 | 0.99 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3FABP7 | |
| SCHEMBL178890 | 0.99 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3FABP7 | |
| SCHEMBL17746959 | 0.99 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205372-A1 | RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-06-26 | — | — | US | claimed |
| WO-2023178313-A2 | RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-09-21 | — | — | WO | claimed |
| US-20260131034-A1 | RADIOPHARMACEUTICALS TARGETING CARBONIC ANHYDRASE IX PROTEINS | NORROY BIOSCIENCE CO LTD (CN) | 2026-05-14 | — | — | US | disclosed |
| US-12564650-B2 | Carbonic anhydrase IX-targeting radioactive diagnostic and therapeutic medicament and method for preparing same | NORROY BIOSCIENCE CO., LTD. (CN) | 2026-03-03 | — | — | US | disclosed |
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | TRUSTEES OF TUFTS COLLEGE | 2026-01-08 | — | — | US | disclosed |
| EP-4637832-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | Tubulis GmbH (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-20250268988-A1 | PTH Prodrugs | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2025-08-28 | — | — | US | disclosed |
| US-20250205372-A1 | RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250177580-A1 | PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSITY | 2025-06-05 | — | — | US | disclosed |
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025070720-A1 | PEPTIDE | ペプチドリーム株式会社 | 2025-04-03 | — | — | WO | disclosed |
| WO-2000003973-A1 | DIACYLHYDRAZINE DERIVATIVES AS INTEGRIN INHIBITORS | MERCK PATENT GMBH (DE) | 2000-01-27 | — | — | WO | disclosed |
| US-5786218-A | INFRARED ANALYSIS BY REACTING WITH A DEUTERIUM CONTAINING REAGENT | ZENECA LIMITED (GB) | 1998-07-28 | — | — | US | disclosed |
| EP-0502926-B1 | ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES | RHONE POULENC RORER INT (US) | 1996-03-13 | — | — | EP | disclosed |
| EP-0541663-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS HAVING GLYCOPROTEIN HORMONE AGONISTIC OR ANTAGONISTIC ACTIVITY | STICHTING CENTRAAL DIERGENEESKUNDIG INSTITUUT (NL) | 1993-05-19 | — | — | EP | disclosed |
| EP-0502926-A1 | ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES. | RHONE POULENC RORER INT (US) | 1992-09-16 | — | — | EP | disclosed |
| EP-0502926-A4 | ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES. | RHONE POULENC RORER INTERNAT H (US) | 1992-07-13 | — | — | EP | disclosed |
| WO-1992002542-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS HAVING GLYCOPROTEIN HORMONE AGONISTIC OR ANTAGONISTIC ACTIVITY | STICHTING CENTRAAL DIERGENEESKUNDIG INSTITUUT (NL) | 1992-02-20 | — | — | WO | disclosed |
| US-5053392-A | Anticoagulants | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-01 | — | — | US | disclosed |
| WO-1991007976-A1 | ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1991-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268988-A1 | PTH Prodrugs | PTH1R, PTMS, PHPT1 | KMT2A 3758/4885HTT 3183/4885EPHX2 675/4885 |
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | FIBP, FRS2, FGFR1 | KMT2A 3715/4885HTT 4827/4885EPHX2 2207/4885 |
| US-20260131034-A1 | RADIOPHARMACEUTICALS TARGETING CARBONIC ANHYDRASE IX PROTEINS | CA9, CA11, CA12 | KMT2A 3456/4885HTT 3998/4885EPHX2 2028/4885 |
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | KMT2A 2834/4885HTT 613/4885EPHX2 579/4885 |
| US-12564650-B2 | Carbonic anhydrase IX-targeting radioactive diagnostic and therapeutic medicament and method for preparing same | CA9, CA12, CA13 | KMT2A 2644/4885HTT 4774/4885EPHX2 2196/4885 |
| US-20250205372-A1 | RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT | QPCT, SSTR5, SSTR4 | KMT2A 2814/4885HTT 321/4885EPHX2 2224/4885 |
| US-20250177580-A1 | PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY | PSMA1, PSMA2, PSMA3 | KMT2A 1216/4885HTT 4046/4885EPHX2 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.